1 to 10 of 50 trials

• AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies

  conditions:	Cancer
  interventions:	darbepoetin alfa
  last updated:	2009 Jan 29
  status:	completed
  sponsor:	Amgen

   

• A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

  conditions:	Anemia ; Neoplasms
  interventions:	Aranesp®
  last updated:	2008 Oct 14
  status:	completed
  sponsor:	Amgen

   

• Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

  conditions:	Non-Myeloid Malignancies ; Anemia ; Cancer
  interventions:	Darbepoetin alfa
  last updated:	2007 Dec 20
  status:	completed
  sponsor:	Amgen

   

• Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

  conditions:	Anemia ; Cancer
  interventions:	Aranesp®
  last updated:	2009 May 7
  status:	completed
  sponsor:	Amgen

   

• Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy

  conditions:	Cancer ; Non-Myeloid Malignancies
  interventions:	rHuEPO ; Darbepoetin alfa
  last updated:	2008 Feb 20
  status:	completed
  sponsor:	Amgen

   

• A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

  conditions:	Anemia ; Non-Myeloid Malignancies
  interventions:	Darbepoetin alfa - 2.25 mcg/kg ; Darbepoetin alfa - 500mcg
  last updated:	2009 Mar 24
  status:	completed
  sponsor:	Amgen

   

• Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

  conditions:	Anemia ; Non-Myeloid Malignancies
  interventions:	Darbepoetin alfa ; Placebo
  last updated:	2008 Feb 20
  status:	completed
  sponsor:	Amgen

   

• Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

  conditions:	Anemia ; Leukemia ; Lymphoma ; Lymphoproliferative Disorder ; Multiple Myeloma and Plasma Cell Neoplasm ; Precancerous/Nonmalignant Condition ; Unspecified Adult Solid Tumor, Protocol Specific
  interventions:	darbepoetin alfa ; ferrous sulfate ; sodium ferric gluconate complex in sucrose ; placebo
  last updated:	2009 May 9
  status:	active, not recruiting
  sponsor:	Mayo Clinic

   

• Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies

  conditions:	Lymphoma ; Breast Neoplasms ; Lung Neoplasms ; Multiple Myeloma ; Chronic Lymphocytic Leukemia
  interventions:	darbepoetin alfa
  last updated:	2009 May 7
  status:	completed
  sponsor:	Amgen

   

• Chemotherapy Related Anemia

  conditions:	Anemia ; Non-Myeloid Malignancies
  interventions:	Darbepoetin alfa SC ; Darbepoetin alfa IV
  last updated:	2008 Sep 11
  status:	completed
  sponsor:	Amgen